Xenoport, Inc. Q1 2008 Earnings Call Transcript Katherine Xu - Credit Suisse Juan Sanchez - Ladenburg Thalmann Presentation Operator Good afternoon.My name is Christine, and I will be your conference operator today.
At this time, I would like to welcome everyone to the XenoPort first...
Amicus Therapeutics Inc. Q1 2008 Earnings Call Transcript Let me begin by saying that as many of you know, Amicus Therapeutics is a bio-pharmaceutical company and that we focus on developing small molecule drugs, known as pharmacological chaperones for the treatment of a broad range of human...
ThromboGenics N.V. - Business Update - Regulated Information ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for vascular disease, eye disease and cancer, is today issuing a business update for the three month period ended 31...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') TSX:ONC ONCY announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for its ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating CALGARY, Canada, May 14 /PRNewswire/ -- Oncolytics Biotech Inc.(News) ('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA...
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.(NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the...
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase QUEBEC CITY, May 14 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc.(News) (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of...
terna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign P QUEBEC CITY, May 14 /CNW Telbec/ - terna Zentaris Inc.(NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's ...
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign QUEBEC CITY, May 14 /CNW Telbec/ - AEterna Zentaris Inc.(NASDAQ: AEZS - News; TSX: AEZ - News), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the...
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results Molecular Insight Pharmaceuticals, Inc.(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.
'During the first quarter, Molecular Insight...
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of - Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3 treatment-experienced patients - Pharmasset, (News) Inc.(Nasdaq: VRUS) has commenced dosing two...
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results , 8:30 AM EST News source: Business Wire Molecular Insight Pharmaceuticals, Inc.(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.
...
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results CAMBRIDGE, Mass.- (Business Wire) Molecular Insight Pharmaceuticals, Inc.
(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.
During...
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript Size: Print Jazz Pharmaceuticals, Inc.(JAZZ) Q1 2008 Earnings Call Executives Matt Fust - CFO Sam Saks - CEO Bob Myers - President Analysts Rich Silver - Lehman Brothers Marc Goodman - Credit Suisse Corey Davis - Natexis Presentation...
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial ...
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (News) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination...
/R E P E A T -- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Co CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for its ...
/R E P E A T -- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Co CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for its ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination With P CALGARY, May 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P ('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for its ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical ...
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P CALGARY, May 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.
Medicines and Healthcare products Regulatory Agency ...
